Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

BioMarin Pharmaceutical (BMRN) is highlighted as a potential growth stock despite its Zacks #3 (Hold) rank, primarily due to strong underlying metrics. The company boasts an 'A' VGM Score and a 'B' Growth Style Score, underpinned by a 23% forecasted year-over-year earnings growth for the current fiscal year. This outlook is further reinforced by seven analysts revising FY2025 earnings estimates higher, pushing the Zacks Consensus Estimate to $4.33 per share, alongside a significant average earnings surprise of 32.8%.

Analysis

BioMarin Pharmaceutical (BMRN) presents a compelling growth case despite its neutral Zacks #3 (Hold) rating, a status which is counterbalanced by strong underlying fundamental metrics. The company is forecasted to deliver significant year-over-year earnings growth of 23% for the current fiscal year, supporting its 'B' grade for Growth and a top-tier 'A' for the composite VGM Score. This positive outlook is further substantiated by recent analyst activity; over the past 60 days, seven analysts have revised their fiscal 2025 earnings estimates higher, pushing the Zacks Consensus Estimate up to $4.33 per share. Furthermore, BioMarin has a demonstrated history of exceeding expectations, boasting an average positive earnings surprise of 32.8%, indicating a pattern of consistent operational outperformance.

Key Decisions for Investors

• Growth-oriented investors should consider placing BMRN on their watchlist, as the forecasted 23% earnings growth and positive analyst revisions suggest fundamental strength that may not be fully reflected in its current neutral rating.
• Given the disconnect between the #3 (Hold) rank and the strong 'A' VGM score, it is prudent to monitor for any potential catalysts, such as clinical trial data or an earnings beat, that could trigger a ratings upgrade.
• Investors should pay close attention to the next earnings release, as the company's significant 32.8% average earnings surprise history suggests a high probability of outperformance which could serve as a key share price driver.